The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.

严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）已引起新型冠状病毒病（COVID-19）的全球大流行。尽管过去一年已经开发出疫苗和中和单克隆抗体 (mAb) 来对抗 COVID-19，但一个主要问题是 SARS-CoV-2 相关变体 (VOC) 的出现。事实上，B.1.1.7（英国）、B.1.351（南非）、P.1（巴西）和 B.1.617.1（印度）等 SARS-CoV-2 VOC 目前在这场大流行中占主导地位。在此，我们发现 2020 年初从恢复期患者收集的血清对 SARS-CoV-2 VOC（而非非 VOC 变体）的结合活性和中和能力严重减弱。此外，我们观察到 VH3-30 mAb 32D4 可以逃避 SARS-CoV-2 VOC，该抗体被证明对野生型 (WT) SARS-CoV-2 表现出高度潜在的中和作用。因此，这些结果表明 SARS-CoV-2 VOC 可能能够在恢复期患者中传播，甚至对医疗对策产生抵抗力。迫切需要针对这些 SARS-CoV-2 VOC 采取新的干预措施。